Myanmar Pharma plans $30M upgrade to compete with Indian imports

The state-owned Myanmar Pharmaceutical Factory (MPF) intends to invest about $30 million of its $46 million budget to upgrade and expand production at its plant in Yangon. MPF is shooting to meet World Health Organization GMP standards so it can better compete against Indian imports, which are winning more of the tenders from the Myanmar Health Ministry, according to the Myanmar Times. The company hopes to nearly double production as well as build a new warehouse, U Win Ko Ko, general manager at MPF, tells the publication. Western companies are also making some inroads. Bayer Healthcare in 2014 bought China's Dihon Pharmaceutical Group, an over-the-counter specialist whose products are sold in Myanmar and other Asian countries. Story | More

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.